HowardABurrisMD

Oncology • Nashville, TN

Hematologic Oncology

President, Clinical Operations and Chief Medical Officer, Sarah Cannon

Join to view full profile

Dr. Burris is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Burris' full profile

Already have an account?

Office
250 25th Ave N
Ste 100
Nashville, TN 37203
Phone+1 615-320-5090
Is this information wrong?

Education & Training

San Antonio Uniformed Services Health Education ConsortiumFellowship, Hematology and Medical Oncology, 1988 - 1991
San Antonio Uniformed Services Health Education ConsortiumResidency, Internal Medicine, 1985 - 1988
University of South Alabama College of MedicineClass of 1985

Certifications & Licensure

TX State Medical License 1991 - 2025
TN State Medical License 1997 - 2025
PA State Medical License 1988 - 1994
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Fellow (FASCO) American Society of Clinical Oncologists, 2010

Clinical Trials

Thalidomide in Combination With Capecitabine in Patients With Metastatic Breast Cancer Start of enrollment: 2001 Apr 01
Terminated
Phase 2
Oral Topotecan Versus Docetaxel in Second-Line Treatment of Non-Small Cell Lung Cancer Start of enrollment: 2000 Nov 01
Completed
Phase 2
Topotecan in Combination With Docetaxel in Refractory and/or Advanced Solid Tumors Start of enrollment: 2002 Feb 01
Completed
Phase 1
Weekly Topotecan in Combination With Carboplatin in Two Different Schedules for Refractory and/or Advanced Solid Tumors Start of enrollment: 2003 May 01
Completed
Phase 1
A Study of 5 Fluorouracil and the Anti-Tumor Activity of ADH300004 and 5 Fluorouracil in Subjects With Incurable Solid Tumors Start of enrollment: 2006 Jan 01
Suspended
Phase 1
Topotecan in Combination With Pemetrexed in Patients With Advanced Malignancies Start of enrollment: 2006 Mar 01
Completed
Phase 1
Safety Study of IHL-305 (Irinotecan Liposome Injection) to Treat Advanced Solid Tumors Start of enrollment: 2006 Sep 01
Completed
Phase 1
A Study of Romidepsin (Depsipeptide) in Combination With Gemcitabine in Patients With Pancreatic and Other Advanced Solid Tumors Start of enrollment: 2006 Jul 01
Completed
Phase 1
A Phase I Study of the Safety, Pharmacokinetics, and Anti-Tumor Activity of TH-302 in Patients With Advanced Solid Tumors Start of enrollment: 2007 Jun 01
Completed
Phase 1
Study of NK012 in Patients With Refractory Solid Tumors Start of enrollment: 2007 Mar 01
Completed
Phase 1
LBH589 and Gemcitabine in the Treatment of Solid Tumors Start of enrollment: 2007 Nov 01
Terminated
Phase 1
LBH589, Paclitaxel, Carboplatin +/- Bevacizumab for Solid Tumors Start of enrollment: 2007 Dec 01
Completed
Phase 1
Phase I Study of KRN330 Monoclonal Antibody in Patients With Colorectal Cancer Start of enrollment: 2007 Jun 01
Completed
Phase 1
Safety Study of SGX523, a Small Molecule Met Inhibitor, to Treat Solid Tumors Start of enrollment: 2008 Jan 01
Terminated
Phase 1
PTK787/ZK222584 With Bevacizumab in Patients With Refractory and/or Advanced Malignancies Start of enrollment: 2004 Oct 01
Completed
Phase 1
A Phase I/II Study of BEZ235 in Patients With Advanced Solid Malignancies Enriched by Patients With Advanced Breast Cancer Start of enrollment: 2006 Dec 21
Completed
Phase 1
LBH589 in Combination With Capecitabine Plus/Minus (±) Lapatinib in Breast Cancer Patients Start of enrollment: 2008 May 01
Completed
Phase 1
SCRI Tissue Testing Registry Start of enrollment: 2010 May 01
Terminated
Study of NK012 and Carboplatin in Solid Tumors With Dose Expansion in Triple Negative Breast Cancer Start of enrollment: 2010 Jul 01
Completed
Phase 1
Safety Study of MGA271 in Refractory Cancer Start of enrollment: 2011 Jul 01
Completed
Phase 1
A Study of CDX-1127 (Varlilumab) in Patients With Select Solid Tumor Types or Hematologic Cancers Start of enrollment: 2011 Oct 01
Completed
Phase 1
Safety Study of VAL-083 in Patients With Recurrent Malignant Glioma Start of enrollment: 2011 Oct 01
Completed
Phase 1, Phase 2
Study to Assess Food Effect on Pharmacokinetics of Entinostat in Subjects With Breast Cancer or Non-Small Cell Lung Cancer Start of enrollment: 2012 May 01
Completed
Phase 1
Evaluate the Safety and Efficacy of TGR 1202 in Patients With Relapsed or Refractory Hematologic Malignancies Start of enrollment: 2013 Jan 07
Completed
Phase 1
Phase I Dose-Escalation, Safety, Pharmacokinetic and Pharmacodynamic Study of BVD-523 in Patients With Advanced Malignancies Start of enrollment: 2013 Mar 01
Completed
Phase 1, Phase 2
Rovalpituzumab Tesirine (SC16LD6.5) in Recurrent Small Cell Lung Cancer Start of enrollment: 2013 Jul 01
Completed
Phase 1, Phase 2
Tissue Procurement Substudy for Participants in Study CP-MGA271-01 Start of enrollment: 2013 Jul 01
Terminated
Phase 1
Phase I Dose Escalation Study of VS-5584 in Subjects With Advanced Non-Hematologic Malignancies or Lymphoma Start of enrollment: 2013 Nov 01
Terminated
Phase 1
Phase I Open Label Dose Escalation Study to Investigate the Safety & Pharmacokinetics of AZD5312 in Patients With Androgen Receptor Tumors Start of enrollment: 2014 May 01
Completed
Phase 1
Study Assessing Activity of Molecularly Matched Targeted Therapies in Select Tumor Types Based on Genomic Alterations Start of enrollment: 2016 Sep 28
Completed
Phase 2
A Safety Study of SGN-2FF for Patients With Advanced Solid Tumors Start of enrollment: 2017 Feb 23
Terminated
Phase 1
Safety and Tolerability of HTI-1066 in Subjects With Advanced Solid Tumors Start of enrollment: 2017 Dec 31
Unknown status
Phase 1
Roles: Contact
CAB-AXL-ADC Safety and Efficacy Study in Adult and Adolescent Patients With Sarcoma Start of enrollment: 2018 Feb 15
Recruiting
Phase 1, Phase 2
Roles: Principal Investigator, Contact
CAB-ROR2-ADC Safety and Efficacy Study in Patients With TNBC or Head & Neck Cancer (Ph1) and NSCLC or Melanoma (Ph2) Start of enrollment: 2018 Jun 27
Recruiting
Phase 1, Phase 2
Roles: Contact, Principal Investigator
Join now to see all

Publications & Presentations

PubMed

A risk analysis of alpelisib-induced hyperglycemia in patients with advanced solid tumors and breast cancer.
Jordi Rodón, David Demanse, Hope S Rugo, Howard A Burris, Rafael Simó, Azeez Farooki, Melissa F Wellons, Fabrice André, Huilin Hu, Dragica Vuina, Cornelia Quadt, Dejan...> ;Breast Cancer Research. 2024 Mar 4
2 citations
Plain language summary of the TOPAZ-1 study: durvalumab and chemotherapy for advanced biliary tract cancer.
Do-Youn Oh, Aiwu Ruth He, Shukui Qin, Li-Tzong Chen, Takuji Okusaka, Arndt Vogel, Jin Won Kim, Thatthan Suksombooncharoen, Myung Ah Lee, Masayuki Kitano, Howard Burris...> ;Future Oncology. 2023 Nov 1
2 citations
Efficacy and safety of rucaparib treatment in patients with BRCA-mutated, relapsed ovarian cancer: final results from Study 10.
Rebecca S Kristeleit, Yvette Drew, Amit M Oza, Susan M Domchek, Susana Banerjee, Rosalind M Glasspool, Judith Balmaña, Lee-May Chen, Manish R Patel, Howard A Burris, T...> ;British Journal of Cancer. 2023 Jan 1
11 citations
First-In-Human Phase I Study of the OX40 Agonist MOXR0916 in Patients with Advanced Solid Tumors.
Kim, T., Burris, H., de Miguel Luken, M., Pishvaian, M., Bang, Y., Gordon, M., Awada, A., Camidge, D., Hodi, F., McArthur, G., Miller, W., Cervantes, A., Chow, L., Les...> ;Clinical Cancer Research. 2022 Aug 15
207 citations
Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer.
Oh, D., Ruth He, A., Qin, S., Chen, L., Okusaka, T., Vogel, A., Kim, J., Suksombooncharoen, T., Ah Lee, M., Kitano, M., Burris, H., Bouattour, M., Tanasanvimon, S., Mc...> ;NEJM Evidence. 2022 Aug 1
1 citations
A real-world retrospective study of the use of Ki-67 testing and treatment patterns in patients with HR+, HER2- early breast cancer in the United States.
Jacqueline Brown, Savannah Scardo, Michael Method, Dan Schlauch, Amanda Misch, Shaita Picard, Erika Hamilton, Suzanne Jones, Howard Burris, David Spigel> ;BMC Cancer. 2022 May 6
15 citations
First-in-Human Phase I/II ICONIC Trial of the ICOS Agonist Vopratelimab Alone and with Nivolumab: ICOS-High CD4 T-Cell Populations and Predictors of Response.
Timothy A Yap, Justin F Gainor, Margaret K Callahan, Gerald S Falchook, Russell K Pachynski, Patricia LoRusso, Shivaani Kummar, Geoffrey T Gibney, Howard A Burris, Sco...> ;Clinical Cancer Research. 2022 Sep 1
2 citations
Discordance in Tumor Mutation Burden from Blood and Tissue Affects Association with Response to Immune Checkpoint Inhibition in Real-World Settings.
Emma G Sturgill, Amanda Misch, Carissa C Jones, Daniel Luckett, Xiaotong Fu, Dan Schlauch, Suzanne F Jones, Howard A Burris, David R Spigel, Andrew J McKenzie> ;The Oncologist. 2022 Mar 11
162 citations
Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer.
Gabriel N Hortobagyi, Salomon M Stemmer, Howard A Burris, Yoon-Sim Yap, Gabe S Sonke, Lowell Hart, Mario Campone, Katarina Petrakova, Eric P Winer, Wolfgang Janni, Pie...> ;The New England Journal of Medicine. 2022 Mar 10
30 citations
Atezolizumab Treatment of Tumors with High Tumor Mutational Burden from MyPathway, a Multicenter, Open-Label, Phase IIa Multiple Basket Study.
Claire F Friedman, John D Hainsworth, Razelle Kurzrock, David R Spigel, Howard A Burris, Christopher J Sweeney, Funda Meric-Bernstam, Yong Wang, Jonathan Levy, Jessica...> ;Cancer Discovery. 2022 Mar 1
9 citations
First-In-Human, First-In-Class, Phase I Trial of the Fucosylation Inhibitor SGN-2FF in Patients with Advanced Solid Tumors.
Khanh T. Do, Laura Q.M. Chow, Karen L. Reckamp, Rachel E. Sanborn, Howard A. Burris, Francisco Robert, D. Ross Camidge, Conor E. Steuer, John H. Strickler, Amy Weise, ...> ;The Oncologist. 2021 Nov 1
5 citations
A Phase II Study Evaluating Orteronel, an Inhibitor of Androgen Biosynthesis, in Patients With Androgen Receptor (AR)-Expressing Metastatic Breast Cancer (MBC).
Denise A. Yardley, Robyn R. Young, Kerin B. Adelson, Andrea Silber, Jose E. Najera, Davey B. Daniel, N. W. Peacock, L Finney, Susan J. Hoekstra, Mythili Shastry, John ...> ;Clinical Breast Cancer. 2021 Oct 28
8 citations
Tumor-Specific and Tumor-Agnostic Molecular Signatures Associated With Response to Immune Checkpoint Inhibitors
Daniel Schlauch, Xiaotong Fu, Suzanne F. Jones, Howard A. Burris, David R. Spigel, James A. Reeves, Andrew J. McKenzie> ;JCO Precision Oncology. 2021 Oct 22
29 citations
Convalescent plasma associates with reduced mortality and improved clinical trajectory in patients hospitalized with COVID-19.
Shanna A. Arnold Egloff, Angela Junglen, Joseph S.A. Restivo, Marjorie Wongskhaluang, Casey Martin, Pratik Doshi, Daniel Schlauch, Gregg Fromell, Lindsay E. Sears, Mic...> ;The Journal of Clinical Investigation. 2021 Oct 15
17 citations
An open-label phase I dose-escalation study of the safety and pharmacokinetics of DMUC4064A in patients with platinum-resistant ovarian cancer.
Joyce F. Liu, Howard A. Burris, Judy S. Wang, Lisa Barroilhet, Martin Gutierrez, Yulei Wang, Anjali Vaze, Renee Commerford, Stephanie Royer-Joo, Voleak Choeurng, Eric ...> ;Gynecologic Oncology. 2021 Oct 6
18 citations
Characterization of patients with long-term responses to rucaparib treatment in recurrent ovarian cancer.
Elizabeth M. Swisher, Rebecca Kristeleit, Amit M. Oza, Anna V. Tinker, Isabelle Ray-Coquard, Ana Oaknin, Robert L. Coleman, Howard A. Burris, Carol Aghajanian, David M...> ;Gynecologic Oncology. 2021 Sep 30
137 citations
Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study
Milind Javle, Mitesh J. Borad, Nilofer S. Azad, Razelle Kurzrock, Ghassan K. Abou-Alfa, Ben George, John D. Hainsworth, Funda Meric-Bernstam, Charles Swanton, Christop...> ;The Lancet. Oncology. 2021 Sep 1
27 citations
Safety and impact of dose reductions on efficacy in the randomised MONALEESA-2, -3 and -7 trials in hormone receptor-positive, HER2-negative advanced breast cancer.
Howard A. Burris, Arlene Chan, Aditya Bardia, J. Thaddeus Beck, Joohyuk Sohn, Patrick Neven, Debu Tripathy, Seock-Ah Im, Stephen Chia, Francisco J. Esteva, Lowell L. H...> ;British Journal of Cancer. 2021 Aug 31
8 citations
Next-Generation Sequencing of Patients With Breast Cancer in Community Oncology Clinics
Emma Sturgill, Amanda Misch, Rebecca Lachs, Carissa Jones, Daniel Schlauch, Suzanne F. Jones, Mythili Shastry, Denise A. Yardley, Howard A. Burris, David R. Spigel, Er...> ;JCO Precision Oncology. 2021 Aug 19
82 citations
Vorasidenib, a Dual Inhibitor of Mutant IDH1/2, in Recurrent or Progressive Glioma; Results of a First-in-Human Phase I Trial.
Ingo K. Mellinghoff, Marta Penas-Prado, Katherine B. Peters, Howard A. Burris, Elizabeth A. Maher, Filip Janku, Gregory M. Cote, Macarena I. de la Fuente, Jennifer Cla...> ;Clinical Cancer Research. 2021 Aug 15
3 citations
OncoAlert Round Table Discussions: The Global COVID-19 Experience.
Gilberto Morgan, Evandro de Azambuja, Kevin Punie, Felipe Ades, Kathrin Heinrich, Nicola Personeni, Ramy Rahmé, Roberto Ferrara, Kevin Pels, Marina Chiara Garassino, M...> ;JCO Global Oncology. 2021 Apr 6
91 citations
First-in-human study of the safety, pharmacokinetics, and pharmacodynamics of first-in-class fatty acid synthase inhibitor TVB-2640 alone and with a taxane in advanced...
Gerald Steven Falchook, Jeffrey R. Infante, Hendrik-Tobias Arkenau, Manish R. Patel, Emma Dean, Erkut Borazanci, Andrew Brenner, Natalie Cook, Juanita Lopez, Shubham P...> ;Eclinicalmedicine. 2021 Mar 30
43 citations
Clinical Cancer Advances 2021: ASCO's Report on Progress Against Cancer.
Sonali M. Smith, Kerri Wachter, Howard A. Burris, Richard L. Schilsky, Daniel J. George, Douglas E. Peterson, Melissa Lynne Johnson, Merry Jennifer Markham, Kathryn Fi...> ;Journal of Clinical Oncology. 2021 Feb 2
9 citations
Extended RAS Analysis of the Phase III EPIC Trial: Irinotecan + Cetuximab Versus Irinotecan as Second-Line Treatment for Patients with Metastatic Colorectal Cancer
Alberto Sobrero, Heinz-Josef Lenz, Cathy Eng, Werner Scheithauer, Gary Middleton, Wen-Feng Chen, Regina Esser, Johannes Nippgen, Howard A. Burris> ;The Oncologist. 2021 Feb 1
58 citations
American Society of Clinical Oncology Road to Recovery Report: Learning From the COVID-19 Experience to Improve Clinical Research and Cancer Care.
Nathan A. Pennell, Melissa S. Dillmon, Laura A. Levit, E. Allyn Moushey, Ajjai Alva, Sibel Blau, Timothy L. Cannon, Natalie R. Dickson, Maximilian Diehn, Mithat Gonen,...> ;Journal of Clinical Oncology. 2021 Jan 10
Join now to see all

Lectures

Maintenance of health-related quality of life in elderly patients treated with ribociclib + letrozole in MONALEESA-2.
2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018
Most Patients Should Be Tested
2018 ASCO Annual Meeting - Chicago, Illinois - 06/1/2018
7th Community Oncology Conference
Global Academy for Medical Education (Elsevier), Las Vegas, Nevada - 3/30/2012

Press Mentions

Hydroxychloroquine Combination Risky for Cancer Patients with COVID-19May 29th, 2020
New Drugs Make Headway Against Lung, Prostate, Colon CancersMay 29th, 2020
Patients with Certain Cancers Are Nearly Three Times as Likely to Die of Covid-19, Study SaysApril 28th, 2020
Join now to see all